Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer

C. Twelves, E. Chmielowska, L. Havel, S. Popat, A. Swieboda-Sadlej, P. Sawrycki, P. Bycott, A. Ingrosso, S. Kim, J. A. Williams, C. Chen, A. J. Olszanski, P. de Besi, J. H. Schiller